The findings suggest that NT5C2 and NT5DC2 may be targets and valuable biomarkers to establish personalized treatments for patients with PAAD, which may help with the development of improved diagnostic and therapeutic modalities to improve patient prognoses. The gene discussed is NT5C2; the disease is pancreatic adenocarcinoma.